α4α7 peptide monomer and dimer antagonists
The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.
1. A method for treating Celiac disease in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide dimer compound comprising two monomer subunits, wherein each monomer subunit comprises the amino acid sequence:
Pen-(N-Me-Arg)-Ser-Asp-Thr-Leu-Pen-Phe(4-tBu)-(β-homo-Glu)-(D-Lys) (SEQ ID NO:153)
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein each monomer subunit comprises a disulfide bond between the two Pen amino acids.
3. The method of claim 1 , wherein the peptide dimer compound further comprises a linker moiety.
4. The method of claim 3 , wherein the linker moiety is bound to the D-Lys amino acids of the two monomer units.
5. The method of claim 3 , wherein the linker moiety is diglycolic acid (DIG).
6. The method of claim 1 , wherein the N-terminus of each monomer subunit is acylated.
7. The method of claim 1 , wherein each monomer subunit comprises a C-terminal free amide.
8. The method of claim 1 , wherein each monomer subunit comprises a disulfide bond between the two Pen amino acids and a linker moiety bound to the D-Lys amino acid, wherein the N-terminus of each monomer subunit is acylated.
9. The method of claim 1 , wherein the peptide dimer compound consists of the structure:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the pharmaceutically acceptable salt thereof is an acetate salt of the peptide dimer compound.
11. The method of claim 1 , wherein the pharmaceutical composition is administered orally.
12. The method of claim 1 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient.
13. The method of claim 1 , wherein the pharmaceutical composition comprises an enteric coating.
14. The method of claim 1 , wherein the peptide dimer compound or pharmaceutically acceptable salt thereof inhibits binding of α4β7 to mucosal addressin cell adhesion molecule (MAdCAM).